sr1001 has been researched along with Hypoxia* in 1 studies
1 other study(ies) available for sr1001 and Hypoxia
Article | Year |
---|---|
Protective effects of resveratrol and SR1001 on hypoxia-induced pulmonary hypertension in rats.
Hypoxic pulmonary hypertension (HPH) is a fatal disease with limited therapeutic strategies. Combination therapy is regarded as the standard of care in PH and becoming widely used in clinical practice. However, many PH patients treated with combinations of available clinical drugs still have a poor prognosis. Therefore, identifying innovative therapeutic strategies is essential for PH. This study is designed to examine the effects of combined prevention with resveratrol and SR1001 on HPH in rats. The effects of combined prevention with resveratrol and SR1001 and each mono-prevention on the development of HPH, Th17 cells differentiation, expression of guanine nucleotide exchange factor-H1 (GEF-H1), Ras homolog gene family member A (RhoA) and Phosphorylated myosin phosphatase target subunit (MYPT1) were examined. HPH and RV hypertrophy occurred in rats exposed to hypoxia. Compared with normoxia group, the hypoxia group showed significantly increased ratio of Th17 cells. After treatment with resveratrol, HPH rats showed an obvious reduction of Th17 cells. SR1001 significantly reduced the increased Topics: Animals; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Hypertension, Pulmonary; Hypoxia; Male; Protein Phosphatase 1; Pulmonary Artery; Rats; Resveratrol; rhoA GTP-Binding Protein; Sulfonamides; Th17 Cells; Thiazoles; Treatment Outcome | 2020 |